Table 2.

Effects of GnRH-agonists (conventional doses) in patients with advanced or recurrent endometrial cancer (EC).

First Author, Year (Reference)	Recruitment Phase	Patient Age	Study Design	Diagnosis (Number of Evaluable Patients)	Intervention	Results
Jeyarajah, 1996 [78] including 17 pts from [77]	not indicated	34–88 years	prospective cohort (2 centers)	recurrent EC, progression onconventional treatment (n = 32) G 1/2 (n = 16) high grade (n = 16)	Leuprorelin-depot 3.75–7.5 mg i.m./month (31 pts) Goserelin-depot s.c. 3.6 mg/month	28% OR duration: 4–86 months no difference between G3 and G1/2 tumors
Covens, 1997 [79]	1993–1995	42–75 years	Multicenter phase II study	recurrent or metastatic EC (n = 25)	Leuprorelin-depot 7.5 mg i.m./month	0% OR 33% SD (1–8 months)
Lhomme, 1999 [80]	1992–1994	46–85 years	Multicenter phase II study	recurrent or advanced EC (n = 23)	Triptorelin-depot 3.75 mg i.m./month	8.7% OR 21.7% SD (4–12 months)
Asbury, 2002 [82]	1996	median age: 71 y	multicenter phase II study	recurrent EC (n = 40)	Goserelin-depot 3.6 mg s.c./month	11% OR

Abbreviations: OR, objective responses. SD, stable disease. i.m., intramuscular. s.c., subcutaneous.